Results 191 to 200 of about 216,413 (307)

From prediction to intervention: Paradigm shifts in causal AI for precision medicine and large‐scale cohorts

VIEW, EarlyView.
Large‐scale cohorts and multimodal biomedical data have enabled powerful predictive models for clinical risk stratification, but prediction alone cannot guide effective interventions. This review introduces causal artificial intelligence as a design‐first framework that integrates target trial emulation, causal discovery, and robust effect estimation ...
Linlin Cao, Yudian Xu, Yifan Chen, Honghao Huang, Wei Xu, Jun Pu   +5 more
wiley   +1 more source

Physician Disagreement With Guidelines as a Critical Barrier to Achieving LDL-C Targets in Very High-Risk Patients: An Implementation Science Study. [PDF]

J Korean Med Sci
Cho KH, Cho YR, Lee SR, Bae JW, Nam CW, Park Y, Hwang JY, Yun KH, Kim W, Kim MC, Sim DS, Hong YJ, Kim JH, Ahn Y, Hahn JY, Jeong MH.   +15 more
europepmc   +1 more source

Effectiveness of a Psychiatrist‐Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Psychotropic medications are associated with serious metabolic adverse effects, which contribute to an increased risk of cardiometabolic comorbidities in patients with severe mental illness (SMI). Several intervention strategies are available to mitigate these metabolic adverse effects; however, data on their utility in real‐world ...
Nicolette Stogios, Femin Prasad, Riddhita De, Kateryna Maksyutynska, Akash PrasannaKumar, Vittal Korann, Tariq Ahmed, Marcos Sanches, Leah Burton, Mohammed A. Alarabi, Tanner Isinger, Michelle Desanti, Rebecca Oliveira, Daphne J. Korczak, Ariel Graff‐Guerrero, Gary Remington, Margaret K. Hahn, Sri Mahavir Agarwal   +17 more
wiley   +1 more source

What anabolic–androgenic steroids reveal about the limits of current harm reduction models

Addiction, EarlyView.
Abstract Background Harm reduction has largely been shaped by responses to psychoactive drug use where the most urgent harms are acute. These models focus on overdose, blood‐borne viruses, and rapid‐onset toxicity related harms. When applied wholesale to anabolic–androgenic steroids (AAS), they obscure the distinctive pharmacology, consumer typologies,
Timothy Piatkowski, Jason M. Nagata, Suzanne Nielsen   +2 more
wiley   +1 more source

Statins targeting mevalonate-geranylgeranyl diphosphate pathway inhibit proliferation in NK/T lymphoma by promoting pyroptosis. [PDF]

Transl Oncol
Wang Y, Mei M, Wang J, Wei L, Zhang M, Zhang M.   +5 more
europepmc   +1 more source

Timely Delivery of Care and the Optimal Care Pathway for People With Colorectal Cancer: A Scoping Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
The “Optimal care pathway for people with colorectal cancer” is a framework designed to support clinicians delivering high‐quality, timely care to patients; however, it is unknown whether this has affected outcomes across Australia. The variable results in this review suggest that this guideline is yet to be integrated nationally. ABSTRACT The “Optimal
Elliott Benjamin Fox, Dennis Perez Castillo, Nathan Bain, Amy Brown   +3 more
wiley   +1 more source

Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. [PDF]

Neuroprotection
Kuan JH, Raghavan RS, Koh DLW, Tan WY, Iezhitsa I, Agarwal R.   +5 more
europepmc   +1 more source

Statin-Mediated Modulation of Nrf2 Signaling: Mechanisms and Therapeutic Implications in Atherosclerosis. [PDF]

Rev Cardiovasc Med
Marzoog BA, Kopylov P.
europepmc   +1 more source

Low testosterone levels in men at age 31 associates with future risk of prediabetes and type 2 diabetes: A birth cohort study

Andrology, EarlyView.
Abstract Objective We aimed to investigate the association of a low serum testosterone concentration with the risk of abnormal glucose metabolism (i.e., prediabetes and type 2 diabetes) in men at a 15‐year follow‐up. Study population and methods In a population birth cohort, men with low testosterone (testosterone < 12.1 nmol/L, n = 136) and normal ...
Tuomisto A, Pinola P, Pesonen P, Franks S, Martikainen H, Tapanainen JS, Niinimäki M, Morin‐Papunen L   +7 more
wiley   +1 more source

Quantifying the Age of Evidence: Lessons From Cardiovascular Drugs. [PDF]

J Eval Clin Pract
Ferreira MBC, Prasad V.
europepmc   +1 more source